Upstream Bio, Inc.

Upstream Bio, Inc.

UPB - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$87.11M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Upstream Bio, Inc.Upstream Bio, Inc.-0.9--70%--
$25.00

Target Price by Analysts

1472.3% upsideUpstream Bio Target Price DetailsTarget Price
$-0.60

Current Fair Value

137.9% downside

Overvalued by 137.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$87.11 Million
Enterprise Value$40.48 Million
Earnings per Share$-2.66
Beta1.39
Outstanding Shares54,783,340

Return

Return on Equity-70.07%ROE
Return on Assets-66.65%
Return on Invested Capital-70.05%

Valuation & Multiples

P/E Ratio-0.92P/E Ratio
PEG-4.17PEG
Price to Sales-Price to Sales
Price to Book Ratio0.4Price to Book Ratio
Enterprise Value to Revenue14.1
Enterprise Value to EBIT-0.25
Enterprise Value to Net Income-1
Total Debt to Enterprise0.02
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 10, 2026
EPS
-$0.75
Est. -$0.73
Revenue
$395,000
Est. $548,800

Next Earnings Call

Expected Date
March 17, 2027
EPS Estimate
-$0.68
Consensus analyst estimate
Revenue Estimate
$267,000
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-▼ 100.00%
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %57.36%▼ 35.81%
Total Invested$164.82M▼ 53.17%
Investors Holding90▼ 63.00%

About Upstream Bio, Inc.

75 employees
CEO: E. Rand Sutherland

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features ver...

Upstream Bio Insider Information FAQ

Stockcircle shows 10 open-market insider sales for Upstream Bio in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.

Questions & Answers